X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 25.9 27.7 93.5% View Chart
P/BV x 6.3 2.1 298.5% View Chart
Dividend Yield % 3.2 0.2 1,302.1%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
IPCA LABS
Mar-17
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,720643 267.5%   
Low Rs1,134503 225.4%   
Sales per share (Unadj.) Rs394.5254.4 155.1%  
Earnings per share (Unadj.) Rs101.816.1 633.4%  
Cash flow per share (Unadj.) Rs116.329.8 390.7%  
Dividends per share (Unadj.) Rs40.001.00 4,000.0%  
Dividend yield (eoy) %2.80.2 1,606.2%  
Book value per share (Unadj.) Rs200.3194.6 102.9%  
Shares outstanding (eoy) m169.22126.20 134.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.62.3 160.6%   
Avg P/E ratio x14.035.7 39.3%  
P/CF ratio (eoy) x12.319.2 63.7%  
Price / Book Value ratio x7.12.9 241.9%  
Dividend payout %39.36.2 631.5%   
Avg Mkt Cap Rs m241,43572,300 333.9%   
No. of employees `00010.913.3 81.9%   
Total wages/salary Rs m8,5596,960 123.0%   
Avg. sales/employee Rs Th6,129.62,413.5 254.0%   
Avg. wages/employee Rs Th785.8523.2 150.2%   
Avg. net profit/employee Rs Th1,581.3152.4 1,037.3%   
INCOME DATA
Net Sales Rs m66,76432,106 207.9%  
Other income Rs m2,156226 955.4%   
Total revenues Rs m68,92032,332 213.2%   
Gross profit Rs m27,2044,448 611.6%  
Depreciation Rs m2,4611,730 142.3%   
Interest Rs m1,859241 771.9%   
Profit before tax Rs m25,0412,703 926.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,414675 949.9%   
Profit after tax Rs m17,2242,028 849.3%  
Gross profit margin %40.713.9 294.1%  
Effective tax rate %25.625.0 102.5%   
Net profit margin %25.86.3 408.4%  
BALANCE SHEET DATA
Current assets Rs m46,62217,340 268.9%   
Current liabilities Rs m32,8439,559 343.6%   
Net working cap to sales %20.624.2 85.2%  
Current ratio x1.41.8 78.3%  
Inventory Days Days74100 74.0%  
Debtors Days Days7957 138.9%  
Net fixed assets Rs m39,02920,779 187.8%   
Share capital Rs m846252 335.3%   
"Free" reserves Rs m31,40024,499 128.2%   
Net worth Rs m33,89024,553 138.0%   
Long term debt Rs m18,6373,517 529.8%   
Total assets Rs m90,13639,595 227.6%  
Interest coverage x14.512.2 118.4%   
Debt to equity ratio x0.50.1 383.9%  
Sales to assets ratio x0.70.8 91.3%   
Return on assets %21.25.7 369.5%  
Return on equity %50.88.3 615.3%  
Return on capital %48.510.5 462.8%  
Exports to sales %43.348.6 89.1%   
Imports to sales %6.914.2 48.2%   
Exports (fob) Rs m28,93415,617 185.3%   
Imports (cif) Rs m4,5844,571 100.3%   
Fx inflow Rs m29,18515,617 186.9%   
Fx outflow Rs m6,0215,828 103.3%   
Net fx Rs m23,1659,790 236.6%   
CASH FLOW
From Operations Rs m27,1322,764 981.6%  
From Investments Rs m-7,014-1,432 489.9%  
From Financial Activity Rs m-14,352-1,591 901.9%  
Net Cashflow Rs m5,767-259 -2,228.2%  

Share Holding

Indian Promoters % 71.5 45.9 155.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.4 61.6%  
FIIs % 12.6 25.3 49.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.4 50.6%  
Shareholders   26,511 36,892 71.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WYETH LTD  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS